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Abstract: Nonsteroidal antiinflammatory drugs (NSAIDs), including selective
cyclooxygenase (COX)-2 inhibitors, have come to play an important role in the pharmacologic
management of arthritis and pain. Clinical trials have established the efficacy of etoricoxib in
osteoarthritis, rheumatoid arthritis, acute gouty arthritis, ankylosing spondylitis, low back
pain, acute postoperative pain, and primary dysmenorrhea. Comparative studies indicate at
least similar efficacy with etoricoxib versus traditional NSAIDs. Etoricoxib was generally
well tolerated in these studies with no new safety findings during long-term administration.
The gastrointestinal, renovascular, and cardiovascular tolerability profiles of etoricoxib have
been evaluated in large patient datasets, and further insight into the cardiovascular tolerability
of etoricoxib and diclofenac will be gained from a large ongoing cardiovascular outcomes
program (MEDAL). The available data suggest that etoricoxib is an efficacious alternative in
the management of arthritis and pain, with the potential advantages of convenient once-daily
administration and superior gastrointestinal tolerability compared with traditional NSAIDs.
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Introduction
Musculoskeletal conditions are often progressive and associated with considerable
pain and disability (WHO 2005). These conditions place a huge burden on society in
terms of lost productivity and the cost of treatment (WHO 2005). Rheumatoid arthritis
(RA), osteoarthritis (OA), and spinal disorders (including chronic low back pain
[LBP]) are among those musculoskeletal conditions with the greatest impact on society
(WHO 2005). Approximately 14% of all primary care visits are for musculoskeletal
pain or dysfunction (ACRCCG 1996). Symptomatic OA affects approximately 10%
of men and 18% of women over 60 years of age (WHO 2005), while RA affects
between 0.3% and 1% of adults worldwide (WHO 2005). Approximately 2.0% of all
disability-adjusted life years are lost due to musculoskeletal diseases, including 1.0%
due to OA, and 0.3% due to RA (WHO 2004).
Current approaches to the management of these conditions are many and varied,
but pharmacologic intervention is usually required at some stage for relief of acute
or chronic pain and inflammation. In patients with RA, treatment with nonsteroidal
antiinflammatory drugs (NSAIDs) is usually required as part of initial drug therapy,
alongside disease-modifying antirheumatic drugs (DMARDs), and/or glucocorticoids
(ACRRAG 2002). Pharmacologic intervention in patients with OA, as an adjunct to
nonpharmacologic strategies, may include the use of acetaminophen or NSAID
therapy (ACRSOG 2002). Analgesic drugs, including NSAIDs, also play a regular
role in the management of other chronic musculoskeletal pain syndromes such as
low back pain and ankylosing spondylitis, and in other painful conditions including
postsurgical dental pain and headache (Argoff 2002).
Selective cyclooxygenase (COX)-2 inhibitors, a subclass of NSAIDs, continue
to have a place in the management of RA and OA (ACRRAG 2002; ACRSOG 2002;
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Cush et al 2006). NSAIDs inhibit the COX-mediated
synthesis of prostaglandins, which are important inter-
mediaries in the development of inflammation and pain.
Traditional NSAIDs inhibit both constitutive COX-1 and
inducible COX-2, two processes which are believed to be
responsible for the adverse effects (primarily gastrointestinal
toxicity) and clinical benefits of treatment, respectively
(Warner and Mitchell 2004). Dyspeptic upper gastro-
intestinal symptoms with chronic use of traditional NSAIDs
often lead to discontinuation by the patient with consequent
inadequate pain control, switching from one NSAID to
another, or the addition of a gastroprotective agent to prevent
or treat upper gastrointestinal symptoms or clinical events
(Watson et al 2004). Major gastrointestinal complications,
such as perforation, ulcers, and bleeding may require visits
to the emergency department, hospitalization, and
endoscopic or barium tests. In addition to discomfort and
inconvenience for the patient, the costs of dealing with these
adverse events are substantial (Moore et al 2004).
In contrast, selective COX-2 inhibitors have greater
affinity for COX-2 than COX-1. Clinical evidence has shown
that selective COX-2 inhibitors have comparable efficacy
with traditional NSAIDs in the treatment of arthritis and
pain, but offer the major advantage of reduced gastro-
intestinal toxicity (Warner and Mitchell 2004), thus
providing physicians with an important therapeutic
alternative. Recently, reports from two long-term studies in
patients with a history of colorectal adenomas have detailed
an increased risk of cardiovascular events associated with
the COX-2 inhibitors celecoxib and rofecoxib compared
with placebo (Bresalier et al 2005; Solomon et al 2005),
leading to questions about the cardiovascular safety of these
agents (Drazen 2005; Psaty and Furberg 2005), and
highlighting the importance of careful patient selection
based on the benefits and risks of treatment.
This article will review available data regarding the
efficacy and tolerability of etoricoxib, a selective COX-2
inhibitor that has been evaluated in arthritis and pain.
Pharmacology
In vitro, etoricoxib exhibits a greater selectivity for COX-2
over COX-1 compared with the COX-2 inhibitors rofecoxib,
valdecoxib, and celecoxib (Riendeau et al 2001; Tacconelli
et al 2002). Etoricoxib binds competitively to COX-2 with
1:1 stoichiometry in a reversible, noncovalent manner
(Riendeau et al 2001). In human whole blood assays,
etoricoxib inhibited COX-2 with an IC50 of 1.1 ± 0.1 µM,
compared with an IC50 of 116 ± 8 µM for COX-1, representing
106-fold selectivity for COX-2 over COX-1 (Riendeau et al
2001). No inhibitory effect was observed against a wide range
of other receptors and enzymes evaluated. Selective COX-2
inhibition was also observed in ex vivo blood samples from
healthy human volunteers who received etoricoxib at various
therapeutic and supratherapeutic doses (Dallob et al 2003).
Etoricoxib produced markedly less interference with the
cardioprotective COX-1-mediated antiplatelet activity of low-
dose aspirin in vitro than other NSAIDs including (in
ascending order of aspirin antagonism) rofecoxib,
valdecoxib, celecoxib, and ibuprofen, reflecting the lower
affinity of etoricoxib for COX-1 (Ouellet et al 2001). These
findings are consistent with results from clinical studies in
which ibuprofen, but not rofecoxib (Catella-Lawson et al
2001) or etoricoxib (Wagner et al 2001), antagonized aspirin
antiplatelet activity. Etoricoxib showed potent, dose-
dependent efficacy similar to other NSAIDs in animal models
of acute inflammation, hyperalgesia, pyresis, and chronic
adjuvant-induced arthritis (Riendeau et al 2001). Preclinical
and clinical data were consistent with the gastrointestinal
tolerability of selective COX-2 inhibition; no effects on
gastrointestinal integrity were observed in animal models as
measured by urinary or fecal excretion of 
51creatinine-
ethylenediamine tetraacetic acid (
51Cr-EDTA), an inert
compound that is not taken up by extravascular tissue after
its absorption from the gastrointestinal tract, but is completely
excreted by the kidney (Riendeau et al 2001). Inhibition of
prostaglandin synthesis in the gastric mucosa was not
significantly different from that of placebo in human
volunteers (Dallob et al 2003).
In healthy volunteers, oral etoricoxib is rapidly and
completely absorbed. It reaches Cmax after approximately
1 hour and has up to 100% absolute bioavailability (Agrawal,
Porras, et al 2003; Rodrigues et al 2003). Absorption is
slowed, but not diminished, following a high-fat meal
meaning that etoricoxib can be administered without dietary
consideration (Agrawal, Porras, et al 2003). Etoricoxib shows
linear pharmacokinetics through doses at least 2-fold higher
than the maximum anticipated clinical dose (120 mg)
(Agrawal, Porras, et al 2003). Steady state conditions are
reached after 7 days of daily administration, with an
accumulation half-life of approximately 22 hours and an
apparent terminal half-life of approximately 25 hours
(Agrawal, Porras, et al 2003), supporting once-daily dosing.
Etoricoxib is extensively metabolized and excreted
mostly in the urine, with less than 1% of the oral dose
recovered intact from urine (Rodrigues et al 2003). It is
metabolized primarily by 6´-methyl hydroxylation in humanTherapeutics and Clinical Risk Management 2006:2(1) 47
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liver microsomes, a process catalyzed in large part (~60%)
by members of the hepatic cytochrome P450 (CYP) 3A
subfamily with lesser contributions by multiple other CYP
isoenzymes including CYP2C9, CYP2D6, CYP1A2, and
possibly CYP2C19 (Kassahun et al 2001). Etoricoxib is a
weak inhibitor of CYP3A and other CYP isoenzymes in vitro
(IC50 > 100 µM) (Kassahun et al 2001), and has a minimal
inhibitory effect on CYP3A activity in healthy volunteers
(Agrawal et al 2004b). Coadministration of CYP3A
inhibitors in healthy volunteers increased the etoricoxib area
under the curve, but this effect was not considered to be
clinically relevant (Agrawal et al 2004b). In contrast, agents
that strongly induce CYP3A may reduce etoricoxib
concentrations below therapeutic levels (Agrawal et al
2004b). Patients with mild to moderate hepatic insufficiency
exhibit reduced clearance of etoricoxib. The etoricoxib dose
should not exceed 60 mg once daily in patients with mild
hepatic insufficiency (Child-Pugh score 5 to 6), and 60 mg
every other day in patients with moderate hepatic
insufficiency (Child-Pugh score 7 to 9). No data are available
for patients with severe hepatic impairment (Child-Pugh
score ≥ 10), and etoricoxib is not recommended for use in
this patient population (Agrawal, Rose, et al 2003). Renal
insufficiency has little impact on etoricoxib pharmacokinetics
and no dosage adjustment is required (Agrawal et al 2004a).
However, etoricoxib, similar to other selective and traditional
NSAIDs, appears to have dose-related renovascular effects
(see renovascular tolerability section) (Curtis et al 2004),
and use of etoricoxib in patients with a creatinine clearance
< 30 ml/min is contraindicated (EMEA 2005a).
Clinical studies
Clinical studies have established the efficacy and tolerability
of etoricoxib in arthritis and pain, and the drug is available
in over 50 countries worldwide. Etoricoxib is approved in
Europe for the symptomatic relief of OA, RA, and the pain
and signs of inflammation associated with acute gouty
arthritis (EMEA 2005a), whereas the US Food and Drug
Administration (FDA) has requested additional efficacy and
safety data prior to approval of etoricoxib. Some countries
in Latin America and Asia have additional indications
including LBP, ankylosing spondylitis, and primary
dysmenorrhea
Efficacy
Etoricoxib in the treatment of osteoarthritis
Clinical studies have shown that etoricoxib is more effective
than placebo, and of similar efficacy to traditional NSAIDs,
in the treatment of OA. A dose-ranging study in 617 patients
with knee OA established that etoricoxib 5 mg to 90 mg
every day (QD) was more effective than placebo after 6
weeks as measured by the Western Ontario and McMaster’s
University OA Index (WOMAC) pain subscale and patient
and investigator global assessments (p < 0.05 each
comparison), with maximal efficacy at a dosage of 60 mg
QD (Gottesdiener et al 2002). The efficacy of etoricoxib
60 mg QD was comparable with that of diclofenac 50 mg
three times daily (TID) in long-term extensions of this study
for up to 52 weeks (Curtis et al 2005) and up to a total of
190 weeks (Fisher et al 2003) Etoricoxib 60 mg QD and
diclofenac 50 mg TID also showed comparable efficacy in
a 6-week, randomized study of 516 patients with hip or knee
OA assessed using the WOMAC pain subscale (Zacher et
al 2003), irrespective of baseline disease severity (Frizziero
et al 2004). Interestingly, in this study etoricoxib had a more
rapid effect with significantly more patients reporting a good
or excellent response within 4 hours of the first dose
compared with diclofenac (Figure 1) (Zacher et al 2003).
The Etoricoxib versus Diclofenac sodium Gastro-
intestinal tolerability and Effectiveness (EDGE) study which
primarily evaluated gastrointestinal tolerability in 7111
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Figure 1 Osteoarthritis PGART 4 hours ± 15 minutes after the first dose of
etoricoxib versus diclofenac. This randomized, double-blind, parallel-group study
evaluated the efficacy and tolerability of etoricoxib 60 mg QD versus diclofenac
50 mg TID over 6 weeks in 516 patients with hip or knee osteoarthritis. The
treatments were of comparable efficacy on all primary and secondary efficacy
endpoints (data not shown), except for the analysis of early efficacy illustrated
here in which a greater percentage of patients reported good or excellent
PGART responses within 4 hours of receiving their first dose of etoricoxib
compared with diclofenac. Copyright 
© 2003. Reproduced with permission from
Zacher J, Feldman D, Gerli R, et al. 2003. A comparison of the therapeutic
efficacy and tolerability of etoricoxib and diclofenac in patients with
osteoarthritis. Curr Med Res Opin, 19:725–36.
*p  = 0.007 for good or excellent PGART with etoricoxib versus diclofenac.
Abbreviations: QD, every day; PGART, Patient Global Assessment of Response
to Therapy; TID, three times daily.Therapeutics and Clinical Risk Management 2006:2(1) 48
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patients with hip, knee, hand, or spine OA, showed sustained
and comparable improvements in Patient’s Global
Assessment of Disease Status (PGADS) with etoricoxib
90 mg QD or diclofenac 50 mg TID at 12 months (Baraf et
al 2004). Two randomized, double-blind, 12-week studies
in a total of 997 patients with hip or knee OA showed that
etoricoxib 60 mg QD and naproxen 500 mg TID were of
comparable efficacy, and superior to placebo, as measured
by WOMAC pain and physical function subscales and
PGADS (Fisher et al 2001; Leung et al 2002). In addition,
patients receiving etoricoxib or diclofenac also experienced
treatment-related significant improvements in social and
emotional quality of life and vitality (Hunsche et al 2002).
Early improvements in patient condition were observed
2 days after initiating etoricoxib treatment (Leung et al 2002)
and then maintained through up to 138 weeks on study
extensions (Reginster et al 2004).
The recommended etoricoxib dosage for OA is 60 mg
QD (EMEA 2005a); however, etoricoxib also appears to
offer effective pain relief at lower doses consistent with the
initial dose-ranging findings (Gottesdiener, 2002). A recent
randomized trial in 528 patients with hip or knee OA
demonstrated that the efficacy of etoricoxib 30 mg QD was
comparable with that of ibuprofen 800 mg TID over 12
weeks on the WOMAC pain and physical functioning
subscales and PGADS (p < 0.001 versus placebo for all
comparisons) (Wiesenhutter et al 2005).
Etoricoxib in the treatment of rheumatoid
arthritis
The efficacy of etoricoxib is similar to, or greater than, that
of conventional NSAIDs in patients with RA. In a
randomized study evaluating etoricoxib doses of 10, 60, 90,
and 120 mg QD in 581 adults with RA, patients receiving
etoricoxib 90 mg or 120 mg QD for 8 weeks achieved similar
improvements in the primary endpoints of patient and
investigator global assessment of disease activity. Both
treatment groups showed significant improvements
compared with placebo (average change from baseline
p < 0.05) (Curtis et al 2001). Moreover, in extensions to this
study the efficacy of etoricoxib 90 mg or 120 mg QD was
maintained, and was similar to that of diclofenac 50 mg TID,
over the subsequent 166 weeks (Curtis et al 2001; Curtis,
Losada, et al 2003). Since etoricoxib 90 mg QD produced
maximal benefit in this study, with no additional efficacy at
higher doses, this is considered the optimal dosage for RA
(EMEA 2005a).
In a randomized study in 816 patients with RA in the
US, etoricoxib 90 mg QD was more effective than naproxen
500 mg TID (p < 0.05) or placebo (p < 0.01) over 12 weeks
for all primary and most secondary endpoints (Figure 2),
including the percentage of patients who achieved an
American College of Rheumatology 20% Response Criteria
(ACR20) response (57.9%, 46.8%, and 27.4%, respectively)
(Matsumoto et al 2002). The efficacy of etoricoxib was
evident after 2 weeks (Matsumoto et al 2002), and was similar
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Figure 2 Global assessment results for etoricoxib versus placebo and naproxen
in patients with rheumatoid arthritis. In this randomized, double-blind,
controlled study, 816 adult patients with rheumatoid arthritis were randomized
to receive etoricoxib 90 mg QD (n = 323), naproxen 500 mg BID (n = 170) or
placebo (n = 323) for 12 weeks. Etoricoxib demonstrated superior efficacy on all
primary endpoints compared with naproxen (p < 0.05) or placebo (p < 0.01).
Efficacy was evident after 2 weeks and was maintained throughout the study
period, as illustrated here for two primary endpoints: patient global assessment
of disease activity (top panel) and investigator global assessment of disease
activity (bottom panel). Copyright 
© 2003. Reproduced with permission from
Matsumoto AK, Melian A, Mandel DR, et al. 2002. A randomized, controlled,
clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol,
29:1623–30.
Abbreviations: BID, twice daily; QD, every day; VAS, visual analog scale.Therapeutics and Clinical Risk Management 2006:2(1) 49
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in patients with or without concomitant DMARD and/or low-
dose corticosteroid therapy (Matsumoto, Zhao, et al 2003).
Etoricoxib exhibited comparable efficacy versus placebo
in a duplicate international study (n = 891), although there
was no significant difference between etoricoxib and
naproxen. This discrepancy in results between the US and
international studies may be due to variances in the use of
concomitant therapies or result from underlying medical or
cultural differences between the populations (Collantes et al
2002). Extensions of the US and international studies showed
that the efficacy of etoricoxib and naproxen was maintained
through 52 weeks (Matsumoto, Collantes, et al 2003).
Etoricoxib in the treatment of acute gouty
arthritis
Within the EU, etoricoxib is approved for the treatment of
acute gouty arthritis at a dosage of 120 mg QD during the
acute symptomatic period (EMEA 2005a). This approval is
based on the results of two clinical trials which indicate
that etoricoxib and indomethacin have comparable efficacy
in treating this painful condition. (Rubin et al 2004;
Schumacher et al 2002) Duplicate randomized studies
enrolling a total of 339 patients presenting with acute gout
showed that etoricoxib 120 mg QD or indomethacin 50 mg
TID for 8 days produced comparable improvements in pain
in the affected joint, patient and investigator assessments of
global treatment response, and joint tenderness and swelling
(Rubin et al 2004; Schumacher et al 2002). The onset of
pain relief was rapid, with similar benefit reported within
4 hours of the first dose of etoricoxib or indomethacin
(Rubin et al 2004; Schumacher et al 2002). An exploratory
analysis in one study (n = 189) showed that etoricoxib
produced significantly greater resolution of erythema after
8 days compared with indomethacin (p = 0.038) (Figure 3)
(Rubin et al 2004), and post-hoc analysis of both studies
indicated that the effectiveness of etoricoxib was due to
significant antiinflammatory and analgesic activity, and not
natural resolution of the disease (Boice et al 2004).
Etoricoxib in the treatment of other painful
conditions
The efficacy of etoricoxib has been established in a variety
of other painful conditions including ankylosing spondylitis
(AS), LBP, acute postoperative pain, and primary
dysmenorrhea. In a randomized study in 387 patients with
AS, etoricoxib 90 mg or 120 mg QD showed superior
efficacy to naproxen 500 mg twice daily (BID) (p < 0.05) or
placebo (p < 0.001) at 6 weeks with respect to spinal pain,
global disease activity, and function (van der Heijde et al
2005). Significant pain relief versus placebo was observed
within 4 hours of the first dose of etoricoxib 90 mg QD and
following the second dose of etoricoxib 120 mg QD, and
superior efficacy versus naproxen was maintained over
52 weeks. In a post-hoc analysis of data from this study,
etoricoxib and naproxen improved axial symptoms in
patients with or without peripheral disease, although patients
without peripheral arthritis showed greater spinal
improvement (Gossec et al 2005). In addition, a small study
(n = 22) suggested that etoricoxib 90 mg QD may reduce
the need for biologic therapy in patients with severe
previously NSAID-refractory AS (Jarrett et al 2004).
Duplicate 12-week studies in a total of 644 patients with
chronic LBP showed that etoricoxib 60 or 90 mg QD
produced significant improvements in pain intensity relative
to placebo at the primary 4-week time point (p < 0.001), and
in most secondary endpoints at 12 weeks (Birbara et al 2003;
Pallay et al 2004). Clinical benefit was achieved as early as
1 week and was maintained throughout the 3 months of the
study, with no significant differences between etoricoxib
dosage groups. In 1147 patients with acute LBP who
completed an open, nonrandomized 6-week study of
etoricoxib 60 to 120 mg QD, improvements from baseline
in physical activity were observed at 2 weeks and
improvements in lumbar pain and functional capacity were
92.0
51.0
15.8
6.9
91.8
55.4
27.1
17.7
0
10
20
30
40
50
60
70
80
90
100
Baseline Day 2 Day 5 Day 8
Study Day
P
a
t
i
e
n
t
s
 
w
i
t
h
 
S
t
u
d
y
 
J
o
i
n
t
 
E
r
y
t
h
e
m
a
 
(
%
)
Etoricoxib 120mg QD (n=103)
Indomethacin 50 mg TID (n= 86) 
*
Figure 3 Improvement in study joint erythema in patients with acute gout
treated with etoricoxib or indomethacin for 8 days. This randomized, double-
blind study compared the efficacy of etoricoxib 120 mg QD versus indomethacin
50 mg TID in 189 patients experiencing an acute attack (≤ 48 hours) of gout. The
treatments produced comparable efficacy on all primary and secondary
endpoints; however, a prespecified exploratory analysis illustrated here showed
that etoricoxib was associated with a greater reduction in the incidence of
erythema than indomethacin, with the different reaching statistical significance at
completion of the study period. Copyright 
© 2004. Reproduced with permission
from Rubin BR, Burton R, Navarra S, et al. 2004. Efficacy and safety profile of
treatment with etoricoxib 120 mg once daily compared with indomethacin
50 mg three times daily in acute gout: a randomized controlled trial. Arthritis
Rheum, 50:598–606.
*p  < 0.05.
Abbreviations: QD, every day; TID, three times daily.Therapeutics and Clinical Risk Management 2006:2(1) 50
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seen at 6 weeks (p < 0.001, each comparison) (Hernandez-
Garduño et al 2005).
Etoricoxib is as effective as high-dose diclofenac in
treating chronic LBP. In a 4-week, randomized, double-
blind, parallel-group study of 446 patients with chronic LBP
(Quebec Task Force on Spinal Disorders Class 1 or 2),
etoricoxib 60 mg QD was as effective as diclofenac 50 mg
TID in relieving LBP as assessed by the Lower Back Pain
Intensity Scale (LBP-IS). The time-weighted average change
from baseline over 4 weeks for the LBP-IS was 33 mm in
each group (95% confidence interval [CI] –36.25, –29.63).
Both etoricoxib and diclofenac improved measures of
physical functioning, and were well-tolerated throughout
the trial (Zerbini et al 2005).
A randomized single dose-response study in 398 patients
with moderate to severe acute pain following dental surgery
showed that etoricoxib 120 mg was the optimal dosage for
this indication. Overall, 93.4% of patients receiving a single
dose of etoricoxib 120 mg had perceptible pain relief, with
a median time to pain relief of 0.4 hours and median time to
use of rescue medication of more than 24 hours (p < 0.001
versus placebo and p < 0.05 versus etoricoxib 60 mg for all
comparisons) (Malmstrom, Sapre, et al 2004). Subsequent
studies have shown that a single dose of etoricoxib 120 mg
has greater overall analgesic efficacy in this setting than
oxycodone 10 mg/acetaminophen 650 mg (Chang et al 2004;
Malmstrom et al 2005) or codeine 60 mg/acetaminophen
600 mg (Malmstrom, Kotey, et al 2004; Malmstrom et al
2005), and comparable efficacy to naproxen 550 mg
(Malmstrom, Kotey, et al 2004). A recent study (n = 228)
also demonstrated comparable pain relief with a single dose
of etoricoxib 120 mg or extended-release naproxen 1000 mg
administered within 72 hours of knee or hip replacement
surgery, and superior analgesic efficacy with etoricoxib
120 mg QD versus placebo over 7 days following surgery
(p < 0.001) (no active comparator group was available for
the latter analysis) (Rasmussen et al 2004). Finally, a single
dose of etoricoxib 120 mg showed analgesic efficacy
superior to placebo, and comparable with naproxen 550 mg,
in a randomized study in 73 women with primary
dysmenorrhea (Malmstrom et al 2003).
Tolerability and patient acceptability
Clinical trial data indicates that etoricoxib has a favorable
tolerability profile and is associated with an improved quality
of life (Hunsche et al 2002; Ramos-Remus et al 2004).
Moreover, clinical trial extensions showed that the
tolerability profile of etoricoxib was maintained without
notable safety findings during prolonged treatment for a total
of 52 to 174 weeks (Fisher et al 2001, 2003; Curtis, Losada,
et al 2003; Matsumoto, Collantes, et al 2003; Reginster et
al 2004; van der Heijde et al 2005). Based on clinical
experience with other NSAIDs, issues of particular interest
in etoricoxib trials included gastrointestinal tolerability,
renovascular effects, and cardiovascular safety.
Gastrointestinal tolerability
Several clinical trials reported superior gastrointestinal
tolerability with etoricoxib compared with traditional
NSAIDs. A 12-week study in 501 patients with OA showed
that etoricoxib 60 mg QD was associated with a lower rate
of ‘nuisance’ gastrointestinal adverse events (eg, abdominal
pain, dyspepsia) (20.1% versus 33.0%) and fewer upper
gastrointestinal perforations, ulcers, or bleeding (PUBs) (0
versus 5 events) compared with naproxen 500 mg BID
(Leung et al 2002). Moreover a pooled analysis of this and
a duplicate study indicates that the favorable gastrointestinal
tolerability of etoricoxib is maintained during long-term
treatment over 138 weeks (0.8% versus 5.9% PUBs)
(Reginster et al 2004). The EDGE study reported a lower
rate of discontinuations due to gastrointestinal adverse
events with etoricoxib 90 mg QD than with diclofenac 50 mg
TID in patients with OA (relative risk [RR], 0.50; p < 0.001)
(Baraf et al 2004). In this study consistent benefit was also
observed within patient subgroups at risk for gastrointestinal
adverse events, including patients using concomitant aspirin
or continuing or initiating gastroprotective therapy (Baraf
et al 2005a). There was no difference with respect to the
incidence of PUBs or new use of gastroprotective agents in
the EDGE study (Merck 2005); however, this was not a
prespecified endpoint and the analysis was confounded by
use of aspirin and gastroprotective agents. An 8-day study
in 189 patients with acute gout showed that etoricoxib
120 mg QD was associated with a lower rate of drug-related
gastrointestinal adverse events than indomethacin 50 mg TID
(7.8% versus 18.6%) (Rubin et al 2004). A 4-week safety
study in 62 healthy volunteers demonstrated that daily fecal
blood loss with etoricoxib 120 mg QD was comparable with
placebo and lower than with ibuprofen 800 mg TID
(p < 0.001) (Hunt, Harper, Callegari, et al 2003).
Results from two large 12-week endoscopy studies in
patients with OA or RA showed that etoricoxib 120 mg QD
was associated with a lower cumulative incidence of
gastroduodenal ulcers (≥ 3 mm) and a smaller increase in
gastroduodenal erosions than naproxen 500 mg BID (Hunt,
Harper, Callegari, et al 2003) or ibuprofen 800 mg TIDTherapeutics and Clinical Risk Management 2006:2(1) 51
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(Hunt, Harper, Watson, et al 2003) (p < 0.01 for each
comparison). In addition, results from several large pooled
analyses also support the favorable gastrointestinal
tolerability profile of etoricoxib (Hunt, Harper, Watson, et
al 2003; Watson et al 2004; Ramey et al 2005). An analysis
of 5441 patients with OA, RA, or AS from 10 clinical trials,
showed that etoricoxib 60 to 120 mg QD was associated
with a lower incidence of PUBs than traditional NSAIDs
(ibuprofen 800 mg TID, diclofenac 50 mg TID, naproxen
500 mg BID) (Table 1) (Ramey et al 2005). The superior
PUB profile of etoricoxib during the first year of treatment
in the pooled population was driven primarily by comparison
with naproxen (Merck 2005). In the pooled analysis, as well
as the EDGE study, the reduction in PUBs with etoricoxib
versus traditional NSAID comparator(s), appeared to be
negated in patients receiving concomitant aspirin therapy
(Merck 2005).
Data from 4782 patients with OA, RA, chronic LBP, or
AS, showed that etoricoxib 60 mg to 120 mg QD was
associated with less discontinuation due to dyspepsia
(p = 0.007) and lower new use of gastroprotective agents
(p < 0.001) compared with the NSAIDs diclofenac and
naproxen (mean follow-up 80.5 versus 73.1 weeks) (Watson
et al 2004).
Renovascular and cardiovascular tolerability
All selective and traditional NSAIDs inhibit prostanoid
biosynthesis (Warner and Mitchell 2004); however, it has
been hypothesized that selective suppression of COX-2-
dependent synthesis of prostacyclin (a vasodilator and
inhibitor of platelet aggregation and vascular smooth muscle
cell proliferation) without concomitant inhibition of COX-
1-dependent synthesis of thromboxane A2 (a vasoconstrictor
and promoter of platelet aggregation and vascular
proliferation), may increase the risk of cardiovascular
adverse effects owing to thromboembolism or elevated blood
pressure in patients predisposed to such events (FitzGerald
2002, 2004; Clark et al 2004; Warner and Mitchell 2004).
Clinical trials have suggested that long term use of celecoxib
and rofecoxib may be associated with more cardiovascular
events than placebo or nonselective NSAIDs (Bombardier
et al 2000; FDA 2001; Bresalier et al 2005; Solomon et al
2005), and this has led to the market withdrawal of rofecoxib
worldwide. However, there has been uncertainty over these
findings as a result of the small number of events reported
and methodological problems with the trials. For example,
the trials were statistically underpowered to evaluate
thrombotic events, comparisons between trials were limited
by the different proportions of patients with RA (an
independent risk factor for cardiovascular disease [Solomon
et al 2003]), and concomitant aspirin therapy or use of a
naproxen comparator group may have had a confounding
cardioprotective effect (FitzGerald 2002; Clark et al 2004;
Warner and Mitchell 2004).
The outstanding questions surrounding the cardio-
vascular safety of traditional NSAIDs and selective COX-2
Table 1 Pooled analysis of upper gastrointestinal safety: perforations ulcers and bleeds with etoricoxib versus nonselective
nonsteroidal antiinflammatory drugs (NSAIDs)* (Ramey et al 2005)
Upper Rate per 100
gastrointestinal Number of patient-years Relative risk
‡
events
† events/patients (%) Patient-years (95% CI) (95% CI) p-value
‡
Confirmed events
Etoricoxib 40/3226 (1.24) 4001.65 1.00 (0.71, 1.36) 0.48 (0.32, 0.73) < 0.001
Nonselective NSAIDs 55/2215 (2.48) 2225.46 2.47 (1.86, 3.22)
All investigator-reported events
Etoricoxib 47/3226  (1.46) 4001.37 1.17 (0.86, 1.56) 0.49 (0.33, 0.72) < 0.001
Nonselective NSAIDs 64/2215 (2.89)  2224.50 2.88 (2.22, 3.67)
Confirmed complicated events
Etoricoxib 19/3226  (0.59) 4007.24 0.47 (0.29, 0.74) 0.59 (0.32, 1.09) 0.09
Nonselective NSAIDs 23/2215 (1.04) 2229.66 1.03 (0.65, 1.55)
All investigator-reported
complicated events
Etoricoxib 22/3226  (0.68) 4007.15 0.55 (0.34, 0.83) 0.55 (0.31, 0.98) 0.41
Nonselective NSAIDs 28/2215 (1.26) 2229.41 1.26 (0.83, 1.82)
*Data from 10 clinical trials in 5441 patients with osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis treated with etoricoxib 60 mg, 90 mg, or 120 mg QD
(average dose, 87.3 mg; n = 3226; median exposure 12.4 patient-months; total exposure 4001.65 patient-years) or nonselective NSAIDs ibuprofen 800 mg TID,
diclofenac 50 mg TID, or naproxen 500 mg BID (n = 2215; median exposure 6.3 patient-months; total exposure 2 225.46 patient-years).
† Gastrointestinal perforation, symptomatic ulcer, or gastrointestinal bleeding.
‡ Based on the Cox proportional hazards model.
Abbreviations: BID, twice daily; CI, confidence interval; NSAIDs, nonsteroidal antiinflammatory drug; QD, every day; TID, three times daily.Therapeutics and Clinical Risk Management 2006:2(1) 52
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inhibitors are important matters that greatly impact clinical
care for patients such as those with RA who require effective
and long-term pain and symptom relief. The available
evidence does not conclusively support a mechanistic effect
of COX-2 inhibitors on hemostasis. Of note, recent research
has shown that acetaminophen also significantly inhibits
prostacyclin and thromboxane synthesis (Schwartz et al
2006), suggesting that there is a general lack of information
regarding the mechanistic effects of commonly used
analgesic agents.
Etoricoxib appears to be associated with a low incidence
of renovascular adverse events (hypertension, lower
extremity edema, or congestive heart failure) consistent with
fluid retention observed with all selective and nonselective
NSAIDs (Curtis et al 2004). The EDGE study reported a
numerically higher incidence of hypertension-related
adverse events and a significantly higher percentage of
patients discontinuing therapy with etoricoxib 90 mg QD
compared with diclofenac 50 mg TID (11.7% versus 5.9%,
respectively, for adverse events; 2.3% versus 0.7%,
respectively, for discontinuations, RR 1.60 with 95% CI
1.06, 2.18) (Merck 2005). In addition, a higher rate of new
hypertension medication use was reported with etoricoxib
compared with diclofenac (27.4 versus 22.3 events per 100
patient-years; RR 1.24, p < 0.001). Serious hypertension-
related adverse events were rare (Merck 2005). In a pooled
analysis of 12-week data from 4770 patients with OA, RA,
or chronic LBP, the risk of renovascular adverse events
associated with etoricoxib 60 mg, 90 mg, or 120 mg QD was
low and generally similar to that observed with naproxen
500 mg BID or ibuprofen 800 mg TID (Curtis et al 2004). It
is therefore important to monitor blood pressure in all
patients taking NSAIDs (FDA 2005a).
Analysis of pooled data from more than 6700 patients
(representing approximately 6500 patient-years of
observation) suggested that treatment with etoricoxib ≥ 60 mg
QD was not associated with an excess risk of serious
thrombotic cardiovascular adverse events (fatal or nonfatal
cardiac, cerebrovascular, or peripheral vascular events
confirmed by a blinded external committee) compared with
placebo (RR 1.11; 95% CI 0.32, 3.81) or non-naproxen
NSAIDs (diclofenac 50 mg TID or ibuprofen 800 mg TID;
RR 0.83, 95% CI, 0.26, 2.64) (Curtis, Mukhopadhyay, et al
2003). There were fewer such events associated with
naproxen 500 mg BID, which was evaluated separately from
other traditional NSAIDs because of its potential cardio-
protective activity (etoricoxib versus naproxen RR 1.70; 95%
CI 0.91, 3.18) (Curtis, Mukhopadhyay, et al 2003).
The EDGE study revealed no clear difference between
etoricoxib and diclofenac with respect to the overall
incidence of confirmed thrombotic cardiovascular events
(1.25 versus 1.15 events per 100 patient years, respectively;
RR 1.07) (Baraf et al 2005b). There were slight differences
in the profile of cardiovascular events with etoricoxib versus
diclofenac (eg, 26 versus 19 cardiac events); however, the
numbers were too small to draw firm conclusions (Baraf et
al 2005b; Merck 2005) and any potential difference appeared
to be ameliorated in patients receiving concomitant aspirin
therapy (FDA 2005c).
The MEDAL Program (Multinational Etoricoxib and
Diclofenac Arthritis Long-term) comparing etoricoxib with
diclofenac in over 34 000 RA and OA patients from three
component clinical studies, EDGE (completed), EDGE 2
and MEDAL (both studies ongoing), over more than 18
months (with some patients receiving treatment for up to
40 months) is underway. This program is the first
noninferiority comparison of thrombotic cardiovascular
events between a traditional NSAID (diclofenac) and a
selective COX-2 inhibitor (etoricoxib), and it will provide
further insight into the long-term cardiovascular safety of
etoricoxib and diclofenac. Additionally, as part of an
ongoing safety surveillance effort, a thrombotic cardio-
vascular event procedure was established in 1998 prior to
phase IIb etoricoxib studies in order to collect cardiovascular
safety data for etoricoxib, NSAID comparators and placebo
across etoricoxib’s clinical development program.
Analysis of the available cardiovascular data for all
COX-2 inhibitors, including etoricoxib, has led both the
FDA and the European Medicines Agency (EMEA) to
request the addition of warnings about the potential for
increased cardiovascular risk in the prescribing information
for these agents (EMEA 2005b; FDA 2005b). In the US,
this directive has been extended to apply to all NSAIDs
(except aspirin), irrespective of their COX-2 selectivity
(FDA 2005b). These warnings highlight the need for careful
patient selection based on evaluation of the benefits and
risks of therapy.
Patient support/disease
management programs
American College of Rheumatologists (ACR) guidelines
indicate that pharmacologic therapies such as NSAIDs,
DMARDs, and/or glucocorticoids should be used alongside
nonpharmacologic strategies (eg, patient education, joint
exercise) in the management of RA (ACRRAG 2002).
COX-2 inhibitors may be selected for drug treatment inTherapeutics and Clinical Risk Management 2006:2(1) 53
Etoricoxib for arthritis and pain
Key pharmacologic features
  Rapidly and completely absorbed via oral 
route
  Suitable for once-daily dosing, without dose 
adjustment (except hepatic insufficiency) 
  Greater COX-2 selectivity than rofecoxib, 
valdecoxib, or celecoxib  
  Less interference with aspirin antiplatelet 
activity compared with other NSAIDs 
ETORICOXIB 
Efficacy*
Osteoarthritis    
 Comparable  with  diclofenac 
 Comparable  with  naproxen 
 Comparable  with  ibuprofen 
Rheumatoid arthritis    
 Comparable  with  diclofenac 
  Comparable with or greater than 
naproxen 
Acute gouty arthritis    
 Comparable  with  indomethacin 
Ankylosing spondylitis    
  Greater than naproxen 
Chronic lower back pain   
  Greater than placebo
†
Postoperative pain   
  Comparable with naproxen  
  Greater than opioid/acetaminophen 
Primary dysmenorrhea    
 Comparable with naproxen 
Tolerability
Overall 
 Generally  well  tolerated 
  No new findings during long-term treatment  
Gastrointestinal    
  Superior to nonselective NSAIDs 
Renal
  Similar to naproxen or ibuprofen 
  Significant increase in hypertension-related adverse events and significantly higher percentage of 
patients discontinuing therapy in the etoricoxib 90mg/day group compared with diclofenac  
150mg/day in the EDGE study 
  Serious hypertension-related adverse events were rare in EDGE 
Cardiovascular  
  Thrombotic event risk similar to non-naproxen NSAIDs 
  COX-2 inhibitor class effect for increased cardiovascular risk in product labeling 
  Ongoing evaluation in MEDAL program 
Hepatic
 Adjust etoricoxib dose in patients with hepatic insufficiency
Figure 4 Clinical summary of etoricoxib in arthritis and pain management.
*Greater efficacy defined here as a statistically significant benefit with etoricoxib versus active comparator in an efficacy study. †An active comparator study has not
been performed.
Abbreviations: EDGE, Etoricoxib versus diclofenac sodium gastrointestinal tolerability and effectiveness study; MEDAL, Multinational etoricoxib and diclofenac
arthritis long-term study; NSAIDs, nonsteroidal antiinflammatory drug.
patients at risk of peptic ulceration (ACRRAG 2002).
Alternatively, low-dose prednisone therapy, a nonacetylated
salicylate, or a nonselective NSAID with concomitant
gastroprotective therapy to reduce gastroduodenal ulceration
(eg, proton pump inhibitor, high-dose H2 blocker, or oral
prostaglandin analog) may be used in high risk patients
(ACRRAG 2002). However, routine use of H2 blockers for
dyspepsia is not recommended due to the potential risk of
other gastrointestinal complications (ACRRAG 2002).
Moreover, patients receiving gastroprotective therapy may
still be at risk of lower gastrointestinal tract events. ACR
guidelines recommend that pharmacologic therapy for OATherapeutics and Clinical Risk Management 2006:2(1) 54
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of the hip or knee should be considered an adjunct to
nonpharmacologic strategies including patient education,
personalized social support, weight loss, and appropriate
physical activity (ACRSOG 2002). COX-2 inhibitors are
considered useful among patients who do not achieve
symptom relief with acetaminophen, and in those where
adverse events to acetaminophen or nonselective NSAIDs
are likely or have occurred (ACRSOG 2002). Analgesics,
including selective COX-2 inhibitors, are an important
component of the management of a variety of other
musculoskeletal pain syndromes (Argoff 2002).
Etoricoxib, like all COX-2 inhibitors, may be associated
with a small increase in the risk of some cardiovascular
adverse events, and this needs to be weighed carefully
against the benefits of treatment, particularly in patients with
underlying cardiovascular risk factors. European etoricoxib
prescribing guidelines indicate that treatment is contra-
indicated in patients with congestive heart failure, poorly
controlled hypertension, established ischemic heart disease,
peripheral arterial disease and/or cerebrovascular disease.
The treatment should be given for the shortest duration
possible at the lowest effective daily dose, and the need for
and response to treatment should be reevaluated periodically
(EMEA 2005a). This is in line with US guidelines for all
prescription and nonprescription NSAIDs (excluding
aspirin) (FDA 2005d).
Economic evaluation in the UK showed that etoricoxib
was a cost-effective option in patients with RA or OA
compared with nonselective NSAIDs plus gastroprotective
therapy (proton pump inhibitors or misoprostol) (Moore et
al 2004). It was also cost effective compared with
nonselective NSAIDs in patients with AS in the UK (Jansen
et al 2005). Etoricoxib is associated with higher treatment
costs than indomethacin for acute gouty arthritis, but this
may be counterbalanced by indirect cost savings and
improved quality of life due to fewer drug-related adverse
effects (Martin et al 2005).
Conclusion
A clinical summary for etoricoxib is presented in Figure 4.
Etoricoxib is a COX-2 inhibitor with a high degree of
selectivity for its target. It provides an alternative to other
selective and traditional NSAIDs in treating patients with
arthritis and other painful conditions. Etoricoxib may be
given to a broad range of patients without need for dosage
adjustment, except in cases of hepatic insufficiency. It is
suitable for once-daily administration, which may facilitate
patient compliance with treatment. Clinical trials have shown
that etoricoxib has at least comparable efficacy and greater
gastrointestinal tolerability compared with nonselective
NSAIDs, and may therefore be particularly suitable for
patients with gastrointestinal risk factors. Results from the
MEDAL Program will provide further insight into the
efficacy and gastrointestinal, renovascular, and
cardiovascular tolerability of etoricoxib. In summary,
etoricoxib provides an effective therapeutic alternative in
the management of arthritic and painful conditions. As for
all drugs, the benefits and risks of treatment should be
evaluated carefully for each patient.
Abbreviations
ACR, American College of Rheumatology; ACR20, American College of
Rheumatology 20% Response Criteria; AS, ankylosing spondylitis; BID,
twice daily; CI, confidence interval; COX, cyclooxygenase; CYP,
cytochrome P450; DMARD, disease-modifying antirheumatic drug;
EDGE, Etoricoxib versus Diclofenac sodium Gastrointestinal tolerability
and Effectiveness study; EMEA, European Medicines Agency; FDA,
United States Food and Drug Administration; IC50, inhibitory concentration
of 50%; LBP, low back pain; MEDAL, Multinational Etoricoxib and
Diclofenac Arthritis Long-term study; NSAID, nonsteroidal anti-
inflammatory drug; OA, osteoarthritis; PGADS, patient’s global assessment
of disease status; QD, once daily; RA, rheumatoid arthritis; RR, relative
risk; TID, three times daily; WOMAC, Western Ontario and McMaster’s
University OA index.
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